

LIFECARE ASA: EXTRAORDINARY GENERAL MEETING

Lifecare ASA, a MedTech company developing next-generation continuous glucose monitoring (CGM) technology, will hold an Extraordinary General Meeting on 12 November 2025 at 16:00 (CET).

Reference is made to the contemplated partially underwritten rights issue announced by the Company on 22 October 2025, with gross proceeds of minimum NOK 80 million and up to NOK 100 million (the "Rights Issue").

In order to facilitate the subscription of shares and exercise of warrants in connection with the Rights Issue, the Board proposes that the General Meeting resolves to reduce the par value of the Company's shares to NOK 0.10.

The meeting will be conducted as a combined physical and digital meeting. Shareholders who wish to participate and vote at the Extraordinary General Meeting must be registered with a user profile in the meeting portal Orgbrain (www.orgbrain.no). Attendance will be possible either in person or digitally through Orgbrain.

The notice with the complete agenda and supporting documents is available at https://lifecare.no/levents/.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.


Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication at 2025-10-22 14:00 CEST.





Attachments

Notice Of EGM 12 November 2025